Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With...
Lung NeoplasmsCarcinoma4 moreThe purpose of this study is to investigate the safety and imaging ability of 111In-DAC when used with planar and SPECT imaging for the detection of lung cancer and brain cancer consistent with metastatic lung cancer.
Chest X-Ray or Chest CT Scan in Patients at High Risk of Developing Lung Cancer
Lung CancerRATIONALE: Diagnostic procedures such as chest x-ray and chest CT scans may be effective in early detection of lung cancer. PURPOSE: Randomized clinical trial to compare the effectiveness of a chest CT scan given once a year with that of a chest x-ray given once a year in detecting lung cancer in patients at a high-risk of developing lung cancer.
Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German...
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring METex14 MutationsThe objective of the study was to compare the therapeutic benefit of capmatinib versus appropriate comparative therapy (ACT) defined by the German HTA agency G-BA for its benefit assessment of capmatinib but also versus the standard of care (SoC) practiced in German routine care. Due to its design as an adjusted, patient-level comparison, the RECAP study addresses the evidence gap due to the single-arm nature of pivotal evidence for capmatinib. For this purpose, data on patients treated with ACT resp. SoC in German routine care has been collected via a retrospective chart review. This data was then used as an external control for a non-randomized, patient-level adjusted comparison with data from the GEOMETRY mono-1 study of capmatinib (NCT02414139). Due to the non-interventional nature of this study, the definition of endpoints as primary or secondary was omitted formally.
Pattern of Isolated Fungi From Bronchoalveolar Lavage Among Patients With Lung Cancer
Lung CancerThe aim of the study is to assess the prevalence and pattern of isolated fungi from patients with lung cancer at the time of diagnosis.
The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis
Lung CancerImmune checkpoint inhibitors have revolutionized lung cancer (LC) treatment, demonstrating a significant improvement in overall survival. However high-grade immune-related adverse events (irAEs) may result in harmful and serious clinical outcomes, even death. Immune-related hepatitis (IRH) is a potentially serious complication of checkpoint blockade, with an incidence of 5%-10% for ICIs monotherapy, including 1%-2% with grade 3 or higher. Therefore, it is particularly important to explore new and better prognostic and predictive biomarkers for IRH.
Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment
Non Small Cell Lung CancerThis study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.
A Chart Review Study of Adults With Advanced NSCLC
Non-small Cell Lung Cancer (NSCLC)The main aim is to see how treatment patterns and drugs might improve care for adults with advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon-20 driven mutations. Past medical records will be reviewed. No clinic visits or procedures will be required.
Neoadjuvant Immunochemotherapy for Lung Cancer
Lung CancerWe retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.
PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening
Lung CancerSmoking Cessation1 moreEducational research study where goal is to test educational materials that help people make informed decisions about lung cancer screening.
dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive...
Non-small Cell Lung CancerTo date, there are no methods to reliably select which patients with non-squamous non-small cell lung cancer (NSCLC) that benefit most from treatment with bevacizumab. Data have shown that high levels of plasma VEGF are prognostic and correlates with a worse disease outcome in some tumour types, including advanced NSCLC. Recent data are suggestive of a predictive value of imaging techniques for early detection of antiangiogenic treatment efficacy in different cancers. To our knowledge there are no presented data available on correlation between changes in diffusion-weighted MR and response to bevacizumab treatment in lung cancer. The current study is designed as a pilot study to prospectively investigate changes in MR variables during treatment with bevacizumab and to detect signals of prognostic and/or predictive value of MR changes during treatment.